This work sheds new light on the mechanism of action of ASCL1 and NEUROD1 in SCLC and demonstrates how specifically targeting certain areas of the genome results in a more effective chemotherapy, thus providing a step forward for precision medicine. This evidence concerns the gene ASCL1 and small cell lung carcinoma.